Cosentyx
E584151
Cosentyx is a biologic medication (secukinumab) used to treat autoimmune inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Cosentyx canonical | 1 |
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medication
ⓘ
pharmaceutical drug ⓘ |
| affectsSystem | immune system ⓘ |
| bindsTo | IL-17A cytokine ⓘ |
| canBeSelfAdministered | true ⓘ |
| hasApprovalYear | 2015 ⓘ |
| hasATCCode | L04AC10 ⓘ |
| hasBrandOwner | Novartis Pharmaceuticals Corporation NERFINISHED ⓘ |
| hasCommonAdverseEffect |
diarrhea
ⓘ
headache ⓘ nasopharyngitis ⓘ upper respiratory tract infection ⓘ |
| hasContraindication | serious active infection ⓘ |
| hasDosageForm |
prefilled autoinjector pen
ⓘ
prefilled syringe ⓘ solution for injection ⓘ |
| hasDrugClass |
immunosuppressive agent
ⓘ
monoclonal antibody ⓘ |
| hasGenericName | secukinumab NERFINISHED ⓘ |
| hasIndication |
active ankylosing spondylitis
ⓘ
active non-radiographic axial spondyloarthritis with objective signs of inflammation ⓘ active psoriatic arthritis ⓘ enthesitis-related arthritis in pediatric patients ⓘ moderate-to-severe plaque psoriasis in adults ⓘ moderate-to-severe plaque psoriasis in pediatric patients ⓘ plaque psoriasis in pediatric patients aged 6 years and older ⓘ |
| hasLoadingDoseRegimen | weekly injections for first 5 weeks in some indications ⓘ |
| hasMaintenanceDoseRegimen | every 4 weeks ⓘ |
| hasMechanismOfAction | inhibits IL-17A cytokine ⓘ |
| hasMolecularType | human monoclonal antibody ⓘ |
| hasRouteOfAdministration | subcutaneous injection ⓘ |
| hasSeriousAdverseEffect | increased risk of infections ⓘ |
| hasWarning | may exacerbate inflammatory bowel disease ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isAdministeredTo |
adults
ⓘ
children ⓘ |
| isApprovedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| isIndicatedFor | chronic systemic inflammatory conditions ⓘ |
| isManufacturedBy | Novartis NERFINISHED ⓘ |
| isUsedFor |
ankylosing spondylitis
ⓘ
autoimmune inflammatory diseases ⓘ non-radiographic axial spondyloarthritis ⓘ plaque psoriasis ⓘ psoriasis ⓘ psoriatic arthritis ⓘ |
| reduces | inflammatory response mediated by IL-17A ⓘ |
| targets | interleukin-17A ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.